Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [916]

CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast...

Dr Hikmat Abdel-Razeq - King Hussein Cancer Center, Amman, Jordan

CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer ( Dr Hikmat Abdel-Razeq - King Hussein Cancer Center, Amman, Jordan )

Gene expression in primary non-small cell lung cancer as a predictor of brain...

Dr Jair Bar - Sheba Medical Center, Tel Hashomer, Israel

Gene expression in primary non-small cell lung cancer as a predictor of brain metastases ( Dr Jair Bar - Sheba Medical Center, Tel Hashomer, Israel )

Integration of DNA and RNA investigations in clinical trials: A laboratory...

Brandon Young - Bowden WIN Precision Oncology Laboratory, Murrieta, USA

Integration of DNA and RNA investigations in clinical trials: A laboratory challenge ( Brandon Young - Bowden WIN Precision Oncology Laboratory, Murrieta, USA )

Implementing national cancer control plans

Dr Eduardo Cazap and Dr Lisa Stevens

Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )

The potential of PARP inhibitors in new cancer groups and in combination with...

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston...

The potential of PARP inhibitors in new cancer groups and in combination with other treatments ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions

Dr Joel Neal - Stanford University, Stanford, USA

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions ( Dr Joel Neal - Stanford University, Stanford, USA )

A phase II study of bemcentinib with pembrolizumab in patients with advanced...

Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona...

A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC ( Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Pembrolizumab increases long-term survival in patients with advanced NSCLC

Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA

Pembrolizumab increases long-term survival in patients with advanced NSCLC ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )

Expanding clinical trial eligibility criteria: Risks and solutions

Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA

Expanding clinical trial eligibility criteria: Risks and solutions ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )

Carfilzomib and irinotecan in relapsed small cell lung cancer

Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA

Carfilzomib and irinotecan in relapsed small cell lung cancer ( Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA )

Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients...

Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA

Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC ( Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA )

Understanding eligibility criteria for clinical trials to increase study size

Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills...

Understanding eligibility criteria for clinical trials to increase study size ( Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills, Georgia )

More from ecancer